

March 2, 2017



Trevena to Host Conference Call on March 8th to Discuss Full Year 2016 Financial Results

Company also announces corporate presentation at the Cowen 37th Annual Health Care Conference on March 8th

KING OF PRUSSIA, Pa., March 02, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host a conference call on Wednesday, March 8, 2017 at 8:00 am EST to review financial results as of and for the year ended December 31, 2016 and to discuss recent corporate highlights.

To join the call, please dial-in at (855) 465-0180 (conference ID: 81728820).

To join a live audio webcast of the call, please visit the [Investor Presentation](#) section of the Company's website (conference ID: 81728820). Following the conclusion of the call, the webcast will be available for replay for 30 days.

Separately, the Company will be webcasting its corporate presentation at the Cowen 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 10:40 a.m. EST in Boston. This presentation will include discussion of how recently-reported data support the Company's plans for regulatory approval and subsequent commercialization of OLINVO™ (oliceridine injection) in the U.S.

To join a live audio webcast of the Cowen presentation, please visit the [Investor Presentation](#) section of the Company's website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.

About Trevena

Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO™ (oliceridine injection). Trevena also has discovered TRV250, in preclinical development for the treatment of migraine, and TRV734 for pain. The Company is actively working on an early stage portfolio of drug discovery programs.

Contacts

Trevena, Inc.

Investors:

Jonathan Violin, Ph.D.
Sr. Director, Investor Relations
610-354-8840 x231

jviolin@trevena.com

or

Media:
Public Relations
PR@trevena.com



Source: Trevena Inc.